These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8712470)

  • 1. Practice guidelines and treatment of patients with von Willebrand's disease.
    Slaughter TF; Greenberg CS
    Anesthesiology; 1996 Aug; 85(2):441-2. PubMed ID: 8712470
    [No Abstract]   [Full Text] [Related]  

  • 2. [Oral administration of factor VIII concentrate preparation to patients with von Willebrand's disease].
    Sakuragawa N; Niiya K; Kondo S
    Nihon Ketsueki Gakkai Zasshi; 1985 May; 48(3):839-42. PubMed ID: 3929525
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrated preparations of Factor 8 (antihaemophilic globulin) in the management of haemophilia A and von Willebrand's disease.
    Castaldi PA; Somer JB; Schiff P; Blackburn CR
    Med J Aust; 1967 Sep; 2(11):481-5. PubMed ID: 5299300
    [No Abstract]   [Full Text] [Related]  

  • 5. von Willebrand's disease: from discovery to therapy - milestones in the last 25 years.
    Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():1-2. PubMed ID: 18786005
    [No Abstract]   [Full Text] [Related]  

  • 6. Correction of prolonged bleeding time in von Willebrand's disease with Humate-P.
    Rose E; Forster A; Aledort LM
    Transfusion; 1990 May; 30(4):381. PubMed ID: 2112280
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety evaluation of Fanhdi
    Jimenez-Yuste V; Núñez L; Alvarez-Roman MT; Martin-Salces M; Haya S; Federici AB; Grifols C; Mairal E; Torres M; Páez A
    Haemophilia; 2022 Jan; 28(1):e23-e27. PubMed ID: 34735040
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic effect of heat-treated factor VIII concentrates in von Willebrand's disease and related disorders: studies in platelet-type von Willebrand's disease].
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Takizawa S; Tamura M; Yamaguchi T; Wada K; Shibata A
    Rinsho Ketsueki; 1987 Dec; 28(12):2117-24. PubMed ID: 3133507
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of the hemostatic defects in Von Willebrand's disease.
    Perkins HA
    Blood; 1967 Sep; 30(3):375-80. PubMed ID: 5298611
    [No Abstract]   [Full Text] [Related]  

  • 11. [Von Willebrand's disease (author's transl)].
    Jacky E; Blättler W; Müller M
    Ther Umsch; 1979 Apr; 36(4):341-4. PubMed ID: 377558
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency.
    Bennett E; Dormandy K
    Lancet; 1966 Oct; 2(7466):731-2. PubMed ID: 4162062
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical profile of the association of P.R1205h and P.R924q in a patient with von Willebrand's disease.
    Woods AI; Kempfer AC; Sánchez-Luceros A; Calderazzo JC; Grosso SH; Lazzari MA
    Haemophilia; 2013 May; 19(3):e180-1. PubMed ID: 23490306
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis and treatment of von Willebrand's disease.
    Livingston RJ; White NS; Catone GA; Hartsock RJ
    J Oral Surg; 1974 Jan; 32(1):65-9. PubMed ID: 4543396
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma product treatment in various types of von Willebrand's disease.
    Berntorp E
    Haemostasis; 1994; 24(5):289-97. PubMed ID: 7843640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
    Weiss HJ; Sussman II; Hoyer LW
    J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-heart surgery in a patient with von Willebrand's disease.
    Komp DM; Nolan SP; Carpenter MA
    J Thorac Cardiovasc Surg; 1970 Feb; 59(2):225-30. PubMed ID: 5309916
    [No Abstract]   [Full Text] [Related]  

  • 20. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.